Variable | Univariable | Multivariable | ||
---|---|---|---|---|
OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value | |
Age | 0.99 (0.98, 1.00) | 0.180 | 0.98 (0.96, 0.99) | 0.001 |
Sex, female | 1.6 (1.03, 2.47) | 0.033 | 1.72 (0.92, 3.20) | 0.087 |
BMI | 0.97 (0.93, 1.02) | 0.247 | 1 (0.95, 1.04) | 0.841 |
Current, ex- smoker | 0.91 (0.61, 1.35) | 0.608 | 1.37 (0.77, 2.43) | 0.283 |
Disease duration | 1.06 (1.04, 1.07) | < 0.001 | 1.06 (1.04, 1.08) | < 0.001 |
Patient global assessment | 1.05 (0.97, 1.13) | 0.21 | 0.89 (0.79, 1.00) | 0.045 |
Physician global assessment | 1.09 (1.01, 1.19) | 0.037 | 1.1 (0.98, 1.23) | 0.121 |
DAS28-ESR | 1.14 (0.99, 1.30) | 0.055 | 1.01 (0.72, 1.41) | 0.973 |
DAS28-CRP | 1.16 (1.01, 1.33) | 0.031 | 0.79 (0.5, 1.26) | 0.325 |
SDAI | 1.02 (1.01, 1.03) | 0.002 | 1.06 (1.01, 1.11) | 0.014 |
CDAI | 1.02 (1.00, 1.03) | 0.023 | 0.97 (0.93, 1.01) | 0.134 |
RAPID3 | 1.05 (1.03, 1.08) | < 0.001 | 1.06 (1.02, 1.1) | 0.002 |
Comorbiditiesa | 1.28 (0.96, 1.72) | 0.084 | 1.32 (0.93, 1.87) | 0.126 |
RF positivity | 0.72 (0.50, 1.03) | 0.073 | 0.65 (0.43, 0.98) | 0.040 |
Anti-CCP Ab positivity | 0.92 (0.61, 1.38) | 0.698 | 1.17 (0.73, 1.88) | 0.510 |
Prior use of methotrexate | 0.36 (0.23, 0.57) | < 0.001 | 0.44 (0.24, 0.81) | 0.008 |
Prior use of sulfasalazine | 0.65 (0.47, 0.9) | 0.008 | 0.59 (0.42, 0.83) | 0.003 |
Prior use of leflunomide | 0.76 (0.57, 1.02) | 0.061 | 0.67 (0.49, 0.92) | 0.013 |
Concomitant methotrexate | 0.57 (0.40, 0.79) | 0.001 | 0.74 (0.47, 1.16) | 0.182 |
Concomitant corticosteroid | 0.93 (0.62, 1.40) | 0.610 | 0.87 (0.57, 1.34) | 0.528 |